ArticleArthritis research & therapy2006
Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine.
Article in Arthritis research & therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 67 citations in OpenAlex.
- Bone marrow dendritic cells deficient for CD40 and IL-23p19 are tolerogenicIranian journal of basic medical sciences · 2020Article
- Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis.Journal of translational medicine · 2019Article
- CD38 Deficiency Downregulates the Onset and Pathogenesis of Collagen-Induced Arthritis through the NF-Journal of immunology research · 2019Article
- Generation, Characteristics and Clinical Trials of Ex Vivo Generated Tolerogenic Dendritic Cells.Yonsei medical journal · 2018Review
- Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases?Immunology · 2018Review
- Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation.Frontiers in immunology · 2018Review
- Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NOD Mice.Frontiers in immunology · 2018Article
- Tolerogenic dendritic cells are efficiently generated using minocycline and dexamethasone.Scientific reports · 2017Article
- Synergistic suppression of autoimmune arthritis through concurrent treatment with tolerogenic DC and MSC.Scientific reports · 2017Article
- Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications.Immune network · 2016Review
- Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4Frontiers in immunology · 2016Article
- DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice.Journal of immunology research · 2015Article
- Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity.Frontiers in immunology · 2015Review
- Isorhamnetin attenuates collagen-induced arthritis via modulating cytokines and oxidative stress in mice.International journal of clinical and experimental medicine · 2015Article
- Regulatory dendritic cells for immunotherapy in immunologic diseases.Frontiers in immunology · 2014Review
- Article
- A mouse model of adoptive immunotherapeutic targeting of autoimmune arthritis using allo-tolerogenic dendritic cells.PloS one · 2013Article
- Exosome removal as a therapeutic adjuvant in cancer.Journal of translational medicine · 2012Article
- Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives.Rheumatology international · 2012Review
- Evaluation of the Effect of the 47 kDa Protein Isolated from Aged Garlic Extract on Dendritic Cells.Iranian journal of basic medical sciences · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional treatments for autoimmune diseases have relied heavily on nonspecific immune suppressants, which possess a variety of adverse effects without inhibiting the autoimmune process in a specific manner. In the present study we demonstrate the effectiveness of antigen-specific, maturation-resistant, tolerogenic dendritic cells (DC) in suppressing collagen-induced arthritis, a murine model of rheumatoid arthritis. Treatment of DC progenitors with the NF-kappaB inhibiting agent LF 15-0195 (LF) resulted in a population of tolerogenic DC that are characterized by low expression of MHC class II, CD40, and CD86 molecules, as well as by poor allostimulatory capacity in a mixed leukocyte reaction. Administering LF-treated DC pulsed with keyhole limpet hemocyanin antigen to naïve mice resulted hyporesponsiveness specific for this antigen. Furthermore, administration of LF-treated DC to mice with collagen-induced arthritis resulted in an improved clinical score, in an inhibited antigen-specific T-cell response, and in reduced antibody response to the collagen. The efficacy of LF-treated DC in preventing arthritis was substantiated by histological examination, which revealed a significant decrease in inflammatory cell infiltration in the joints. In conclusion, we demonstrate that in vitro-generated antigen-specific immature DC may have important potential as a tolerogenic vaccine for the treatment of autoimmune arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.